Though Biogen Idec is a recognized pioneer in the field of large-molecule biologic-based therapeutics, we are also dedicated to advancing our small molecule programs, several of which are in late-stage clinical trials (Phase 2 or beyond).
Some of our key small molecule program include:
- BG-12 and Fampridine-SR for multiple sclerosis
- HSP90 for solid cancer tumors
- BIIB014 for Parkinson's disease
- Lixivaptan for acute heart failure with hyponatremia
High-impact career opportunities within our small-molecule programs exist in a variety of departments and capacities – including Research, Technical Development, Contract Manufacturing, and CMC. We currently have small molecule openings in Cambridge, Massachusetts (our corporate headquarters) and Zug, Switzerland (our international headquarters).
For detailed job descriptions, view all small molecule openings.
